Efficacy

Fampyra (Fampridine) Efficacy in Multiple Sclerosis

Fampyra, known generically as fampridine, is a medication approved for use in improving walking in patients with Multiple Sclerosis (MS). This potassium channel blocker is believed to enhance nerve signal conduction in damaged nerves, which can be impaired in individuals with MS. Clinical trials have demonstrated that fampridine can lead to a modest improvement in walking speed in a subset of patients with MS. The efficacy of fampridine is typically assessed through timed walking tests, where some patients have shown a consistent improvement in their walking ability compared to those on placebo.

However, it is important to note that not all patients with MS respond to fampridine, and its benefits can vary. The drug's efficacy is often evaluated on an individual basis, and treatment continuation is usually contingent on demonstrating a measurable improvement in walking ability. In clinical practice, the response to fampridine is assessed during the first few weeks of treatment, and if no significant benefit is observed, the treatment is often discontinued.

Briumvi (Ublituximab-xiiy) Efficacy in Multiple Sclerosis

Briumvi, also known as ublituximab-xiiy, is a monoclonal antibody that has been evaluated for the treatment of relapsing forms of Multiple Sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Ublituximab-xiiy targets a specific protein called CD20 found on the surface of B cells, which are a type of immune cell implicated in the pathogenesis of MS. By depleting these B cells, ublituximab-xiiy aims to modulate the abnormal immune response that attacks the myelin sheath of nerve fibers in MS.

The efficacy of Briumvi in MS has been investigated in phase II and III clinical trials. Results from these studies have shown that ublituximab-xiiy can significantly reduce the annualized relapse rate in patients with relapsing forms of MS compared to other treatments or placebo. Additionally, ublituximab-xiiy has demonstrated a reduction in the number of new or enlarging T2 lesions and gadolinium-enhancing lesions on MRI, which are markers of disease activity in MS. These findings suggest that Briumvi may offer a promising therapeutic option for managing relapsing forms of MS, with a potential impact on slowing disease progression and reducing relapse frequency.